Pharvaris (PHVS) Capital Leases (2021 - 2026)

Pharvaris' (PHVS) quarterly Capital Leases came in at -$19.2 billion in Q3 2024, up 59.0% on a QoQ basis from -$46.9 billion in Q4 2023.

Analysis

Pharvaris (PHVS) Capital Leases (2021 - 2026) Analysis & Trends

Pharvaris (PHVS) has 2 years of Capital Leases data on file, last reported at -$19.2 billion in Q3 2024.

Quarterly Capital Leases changed N/A year-over-year to -$19.2 billion in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$19.2 billion (changed N/A YoY) and the FY2023 annual result came in at -$47.1 billion, changed N/A from the prior year.
Capital Leases grew to -$19.2 billion in Q3 2024, from -$46.9 billion in the prior quarter.
In the past five years, Capital Leases ranged from a high of -$19.2 billion in Q3 2024 to a low of -$46.9 billion in Q4 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.51 Bn	130.66 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.24 Bn	77.25 Bn	3.93 Bn
3	Argenx Se	63.46 Bn	58.28 Bn	1.37 Bn
4	Moderna	57.89 Bn	52.75 Bn	52.00 Mn
5	Revolution Medicines	44.02 Bn	44.02 Bn	-
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.49 Bn	32.19 Bn	992.69 Mn
8	Royalty Pharma	28.43 Bn	27.59 Bn	-
9	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
10	Pharvaris	2.11 Bn	1.74 Bn	85,072.10

Historic Data

Download Data